VidaMed goes public
This article was originally published in Clinica
Executive Summary
VidaMed, a developer of systems for the treatment of benign prostatic hyperplasia (BPH), went public with the sale of 3.1 million shares on June 21st. At a launch price of $6.50, a third below the price range mentioned in the prospectus, this was expected to raise in excess of $18 million net.